Logo image of CDT

CDT EQUITY INC (CDT) Stock Fundamental Analysis

NASDAQ:CDT - US20678X3044 - Common Stock

1.33 USD
-0.02 (-1.48%)
Last: 8/29/2025, 8:11:04 PM
1.3012 USD
-0.03 (-2.17%)
After Hours: 8/29/2025, 8:11:04 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CDT. CDT was compared to 55 industry peers in the Life Sciences Tools & Services industry. CDT has a bad profitability rating. Also its financial health evaluation is rather negative. CDT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CDT has reported negative net income.
In the past year CDT has reported a negative cash flow from operations.
CDT Yearly Net Income VS EBIT VS OCF VS FCFCDT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

CDT has a Return On Assets of -250.86%. This is amonst the worse of the industry: CDT underperforms 96.36% of its industry peers.
With a Return On Equity value of -567.89%, CDT is not doing good in the industry: 92.73% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -250.86%
ROE -567.89%
ROIC N/A
ROA(3y)-32724%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CDT Yearly ROA, ROE, ROICCDT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 -20K -40K -60K -80K

1.3 Margins

CDT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CDT Yearly Profit, Operating, Gross MarginsCDT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for CDT has been reduced compared to 1 year ago.
The debt/assets ratio for CDT is higher compared to a year ago.
CDT Yearly Shares OutstandingCDT Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 20M 40M 60M
CDT Yearly Total Debt VS Total AssetsCDT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 2M 4M 6M

2.2 Solvency

Based on the Altman-Z score of -13.70, we must say that CDT is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -13.70, CDT is doing worse than 92.73% of the companies in the same industry.
A Debt/Equity ratio of 0.53 indicates that CDT is somewhat dependend on debt financing.
The Debt to Equity ratio of CDT (0.53) is worse than 65.45% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.53
Debt/FCF N/A
Altman-Z -13.7
ROIC/WACCN/A
WACCN/A
CDT Yearly LT Debt VS Equity VS FCFCDT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 2M -2M -4M -6M -8M -10M

2.3 Liquidity

CDT has a Current Ratio of 1.45. This is a normal value and indicates that CDT is financially healthy and should not expect problems in meeting its short term obligations.
CDT has a worse Current ratio (1.45) than 76.36% of its industry peers.
CDT has a Quick Ratio of 1.45. This is a normal value and indicates that CDT is financially healthy and should not expect problems in meeting its short term obligations.
CDT has a Quick ratio of 1.45. This is in the lower half of the industry: CDT underperforms 61.82% of its industry peers.
Industry RankSector Rank
Current Ratio 1.45
Quick Ratio 1.45
CDT Yearly Current Assets VS Current LiabilitesCDT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

0

3. Growth

3.1 Past

CDT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16775.82%.
EPS 1Y (TTM)-16775.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-401.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CDT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CDT Price Earnings VS Forward Price EarningsCDT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CDT Per share dataCDT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -50 -100 -150

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CDT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CDT EQUITY INC

NASDAQ:CDT (8/29/2025, 8:11:04 PM)

After market: 1.3012 -0.03 (-2.17%)

1.33

-0.02 (-1.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-14 2025-08-14
Earnings (Next)11-10 2025-11-10
Inst Owners1.3%
Inst Owner Change-91.83%
Ins Owners0.94%
Ins Owner Change2.62%
Market Cap4.07M
AnalystsN/A
Price TargetN/A
Short Float %2.55%
Short Ratio0.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.15
P/tB 1.15
EV/EBITDA N/A
EPS(TTM)-168.76
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-4.17
FCFYN/A
OCF(TTM)-4.03
OCFYN/A
SpS0
BVpS1.15
TBVpS1.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -250.86%
ROE -567.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32724%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.53
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 97.59%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.45
Quick Ratio 1.45
Altman-Z -13.7
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16775.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-401.17%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-126.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-242.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-230.32%
OCF growth 3YN/A
OCF growth 5YN/A